Baker Bros. Advisors LP Nurix Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,882,125 shares of NRIX stock, worth $33.7 Million. This represents 0.45% of its overall portfolio holdings.
Number of Shares
3,882,125
Previous 3,882,125
-0.0%
Holding current value
$33.7 Million
Previous $46.1 Million
4.12%
% of portfolio
0.45%
Previous 0.55%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
174Shares Held
79.4MCall Options Held
126KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$59.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$52.6 Million2.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$38.7 Million0.0% of portfolio
-
Commodore Capital LP New York, NY3.95MShares$34.2 Million4.19% of portfolio
-
Redmile Group, LLC San Francisco, CA3.73MShares$32.4 Million5.17% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $409M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...